DAX+0,02 % EUR/USD+0,09 % Gold+0,13 % Öl (Brent)-0,29 %

Original-Research Expedeon AG (von GBC AG): BUY

Nachrichtenagentur: dpa-AFX
03.12.2019, 11:01  |  677   |   |   

^

Original-Research: Expedeon AG - von GBC AG

Einstufung von GBC AG zu Expedeon AG

Unternehmen: Expedeon AG
ISIN: DE000A2YN801

Anlass der Studie: Research Comment
Empfehlung: BUY
Kursziel: 3.20 Euro
Kursziel auf Sicht von: 31/12/2020
Letzte Ratingänderung:
Analyst: Cosmin Filker, Marcel Goldmann

Sale of the immunology and proteomics divisions will net EUR120 million (EUR2.29 per share), DNA business is to be expanded

On 11/11/2019, Expedeon AG reached an agreement with antibody online distributor Abcam plc for the planned sale of the immunology and proteomics businesses. If the deal is approved at the extraordinary general meeting set for 19/12/2019, the transaction is expected to be closed on 01/01/2020. According to the agreement, a total purchase price of EUR120 million (in cash) is to be paid for the purchase of the two divisions, with EUR105.6 million payable immediately and EUR14.4 million paid over a two-year period.

The business segments about to be sold were acquired by Expedeon AG in recent financial years as part of intensive M&A activities. Starting with the purchase of the now eponymous proteomics specialist Expedeon in 2016, the electrophoresis equipment provider C.B.S. Scientific was purchased in late 2016. These acquisitions were followed by the purchase of protein measurement companies Innova Biosciences (2017) and TGR Biosciences (2018). The total purchase price for these four companies is EUR39.8 million, i.e. appreciably less than the sale price of around EUR120 million that will now be realised. Expedeon AG's current market capitalisation of EUR83.2 million would also be significantly exceeded with the purchase price.
According to our findings, the divisions and products to be sold account for around 90% of Expedeon's annual sales and should make a sharply positive earnings contribution. With annual sales of these products expected to be around EUR14.4 million for 2019, this would represent a purchase price multiple exceeding 8.

After the planned deal is finalised, the product area of the 'genomics' segment is to remain in Expedeon AG (the name of which is proposed to be changed to '4BaseBio AG' at the general meeting) with the key products TruePrimeTM, SunScript(R) and with products of the electrophoresis sector of the former C.B.S. Scientific. The operating figures for the coming financial year would also be marked by the loss of the major part of the sales proceeds and earnings contribution. In 2020, the company should post only around 10% of the current revenue level, or around EUR1.6 - 2.0 million. From the current standpoint, however, we cannot yet estimate the actual impact, and for this reason we are not changing our previous forecasts for the time being (see Research report dated 07/10/2019). The company specifically expects that overall 38% of the operating assets will not be sold. US subsidiary Expedeon Inc. is not to be included in the sale assets, but is to be transferred prior to the sale from Expedeon Holdings Ltd. to Expedeon AG.

Seite 1 von 2
Diesen Artikel teilen

Goldbarren bequem von zuhause aus kaufen, hier!

Diskussion: Expedeon AG (vormals: Sygnis AG)
Wertpapier

Mehr zum Thema
Klicken Sie auf eines der Themen und seien Sie stets dazu informiert. Mehr Informationen hier.
EuroBörseGoldEURRating


0 Kommentare
Rating: BUY
Analyst: GBC

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Aus der Community
LUS Wikifolio-Index BITCOIN, ETHEREUM & GOLD Index Zertifikat Open-End (LASW)
Chart: arniarni
LUS Wikifolio-Index Performance von Kryptowährungen Index Zertifikat Open-End (LASW)
Chart: arniarni

Meistgelesene Nachrichten des Autors

Titel
Titel
Titel
Titel